<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03642509</url>
  </required_header>
  <id_info>
    <org_study_id>Occlusion-AF-AUH250418-32</org_study_id>
    <nct_id>NCT03642509</nct_id>
  </id_info>
  <brief_title>Left Atrial Appendage Occlusion Versus Novel Oral Anticoagulation for Stroke Prevention in Atrial Fibrillation</brief_title>
  <acronym>Occlusion-AF</acronym>
  <official_title>Left Atrial Appendage Occlusion Versus Novel Oral Anticoagulation for Stroke Prevention in Atrial Fibrillation. A Multicenter Randomized Clinical Trial. (Occlusion-AF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aalborg University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sahlgrenska University Hospital, Sweden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Karolinska University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Turku University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Haukeland University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Helsinki University Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Atrial fibrillation (AF) is progressively common, and increases the risk of stroke five-fold.
      Oral anticoagulation is the mainstay therapy; however, it increases the risk of bleeding.
      Moreover, 30% with AF and at risk of stroke are not in relevant anticoagulation. The
      randomized PROTECT-AF trial has demonstrated the superiority of left atrial appendage
      occlusion (LAAO) as compared to warfarin for prevention of the combined endpoint of stroke,
      major bleeding and cardiovascular mortality. However, studies comparing LAAO to therapy with
      novel oral anticoagulants (NOAC) have not been carried out.

      This study aims to assess the effect of left atrial appendage occlusion (LAAO) to reduce the
      incidence of stroke, systemic embolism, major bleeding and all-cause mortality in patients
      with atrial fibrillation (AF) and a prior ischemic stroke or transient ischemic attack (TIA).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An investigator-initiated multicenter, randomized open-label non-inferiority trial with
      blinded outcome evaluation (PROBE design). The active comparison LAAO is tested against NOAC
      therapy in a 1:1 stratified randomization. Patients should have AF, and an ischemic stroke or
      TIA within 6 months prior to enrollment. In total 750 patients will be included. Follow-up
      will be based on in-office and telephone follow-up during the first 3 years after
      randomization, along with up to 10 years long-term follow-up through the National Patient
      Registries.

      The main study outcomes: The primary outcome is a composite of stroke (hemorrhagic or
      ischemic), systemic embolism, major bleeding or all-cause mortality assessed after at least
      two years follow-up for the last enrolled patient. Secondary outcomes will examine early and
      late safety outcome measures. The long-term outcome will be assessed up to 10-years after
      randomization through the National Patient Registries.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2019</start_date>
  <completion_date type="Anticipated">October 1, 2030</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Open-label study with blinded outcome assessment by an independent clinical event committee</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Composite endpoint of stroke (ischemic and hemorrhagic), systemic embolism, major bleeding and all-cause mortality.</measure>
    <time_frame>Up to 5-years from randomization</time_frame>
    <description>The primary endpoint is the combined rate of stroke, systemic embolism, major bleeding and all-cause mortality.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of ischemic stroke</measure>
    <time_frame>2-, 3-, 5- and 10-years</time_frame>
    <description>The occurrence of an acute onset of a focal neurological deficit of presumed vascular origin lasting for ≥ 24 hours or resulting in death. Stroke is categorized as ischemic based on computed tomography (CT) or magnetic resonance imaging (MRI) of the brain or autopsy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of hemorrhagic stroke</measure>
    <time_frame>2-, 3-, 5- and 10-years</time_frame>
    <description>The occurrence of an acute onset of a focal neurological deficit of presumed vascular origin lasting for ≥ 24 hours or resulting in death. Stroke is categorized as hemorrhagic based on computed tomography (CT) or magnetic resonance imaging (MRI) of the brain or autopsy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of systemic embolism</measure>
    <time_frame>2-, 3-, 5- and 10-years</time_frame>
    <description>The occurrence of an acute vascular insufficiency or occlusion of the extremities or any non-CNS organ associated with clinical, imaging, surgical or autopsy evidence of arterial occlusion in the absence of other likely mechanism (e.g. trauma, atherosclerosis, or instrumentation).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of major or life-threatening bleeding</measure>
    <time_frame>2-, 3-, 5- and 10-years</time_frame>
    <description>The occurrence of an overt bleeding associated with one or more of the following: decrease in hemoglobin of at least 3.0 g/dL, transfusion of 2 or more units of blood, causing hospitalization, requiring surgery, causing discontinuation of all antithrombotic therapy or pericardial bleeding with/without tamponade or occurring during the index LAAO procedure or during hospitalization for the index procedure (major bleeding). Life-threatening bleeding is defined as fatal bleeding, causing hypovolaemic shock or severe hypotension requiring vasopressor therapy or intervention, symptomatic bleeding in a critical organ (intracranial, intraspinal, intraocular, intramuscular with compartment syndrome, pericardial bleeding after hospitalization for the index LAAO) or overt bleeding with decrease in hemoglobin ≥ 5 g/dL or requiring transfusion of ≥ 4 units of blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of all-cause mortality</measure>
    <time_frame>2-, 3-, 5- and 10-years</time_frame>
    <description>The occurrence of death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Transient ischemic attack (TIA)</measure>
    <time_frame>2-, 3-, 5- and 10-years</time_frame>
    <description>an episode of neurological dysfunction caused by focal brain, spinal cord or retinal ischemia leading to symptoms lasting less than 24 hours, without acute infarction based on neuroimaging.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with a device-related complication</measure>
    <time_frame>2 months</time_frame>
    <description>A complication related to the presence of the device. Device-related complications include:
Device embolization
Device erosion
Clinically significant device interference with surrounding structures. This includes structures at the implant location (circumflex coronary artery, mitral valve, pulmonary artery, pulmonary vein) or cardiovascular structures in the vicinity of the location to which the device migrated (if applicable).
Device thrombus
Device fracture
Device infection/endocarditis/pericarditis
Device perforation/laceration
Device allergy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with a procedure-related complication</measure>
    <time_frame>2 months</time_frame>
    <description>All complications related to the LAAO-procedure will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with a device success</measure>
    <time_frame>2 months</time_frame>
    <description>Device deployed and implanted in correct position</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with technical success</measure>
    <time_frame>2 Months</time_frame>
    <description>Exclusion of the left atrial appendage (LAA) achieved without device-related complications and no leak &gt;5 mm on color Doppler TEE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with procedural success</measure>
    <time_frame>2 months</time_frame>
    <description>Technical success and no procedure-related complications, except uncomplicated device embolization (i.e. device embolization resolved by percutaneous retrieval during the procedure without surgical intervention or damage to surrounding cardiovascular structures).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with peri-device leaks at follow-up imaging</measure>
    <time_frame>2 months</time_frame>
    <description>Detection of any peri-device flow/gap at follow-up cardiac CT/TEE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in functional status based on Modified Rankin Scale</measure>
    <time_frame>24 months</time_frame>
    <description>The Modified Rankin scale is used to measure the degree of disability or dependence in daily activities caused by a stroke. The scale runs from 0-6, from no symptoms (0) to death (6).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Quality of life</measure>
    <time_frame>12 months</time_frame>
    <description>Based on patient self-reported EuroQol-5D questionnaires. The EuroQol-5D is a standardized instrument to measure health-related quality of life. It includes five self-rated dimensions of mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The questionnaire have 3 levels of severity for each of the five dimensions. It also includes a visual scale from 0 (worst thinkable health condition) to 100 (best thinkable health condition) to report an overall measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance to NOAC</measure>
    <time_frame>2-, 3-, 5-, and 10-years</time_frame>
    <description>Adherence to assigned NOAC therapy will be assessed through the National Prescription Registries.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in neurological status based on National Institute of Health (NIH) Stroke scale score</measure>
    <time_frame>12 months</time_frame>
    <description>Assessed by the NIH stroke scale at baseline and 12 month follow-up. A scale to quantify the neurological impairment caused by a stroke. It includes 11 items, each of which scores a specific ability between 0 to 4. For each item, a score of 0 typically indicates normal function in that specific ability, while a higher score is indicative of some level of impairment. The individual scores are summed to calculate the total NIH Stroke Scale score, that can range from 0 to 42, with 0 being no symptoms.
Score 0: No stroke symptoms
Score 1-4: Minor stroke
Score 5-15: Moderate stroke
Score 16-20: Moderate to severe stroke
Score 21-42: Severe stroke</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Minor bleeding</measure>
    <time_frame>24 months</time_frame>
    <description>Any bleeding clinically mentionable that does not qualify as life-threatening, disabling or major.</description>
  </other_outcome>
  <other_outcome>
    <measure>Comparison of the cost-effectiveness of LAAO and NOAC therapy</measure>
    <time_frame>24 months</time_frame>
    <description>All costs and cost-effectiveness will be evaluated and compared between the two diagnostic strategies.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">750</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>LAAO group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be treated with transcatheter left atrial appendage occlusion. The LAAO may be performed with the Amulet or Watchman device.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NOAC group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be treated with one of the currently available NOAC drugs; Apixaban, Dabigatran, Edoxaban or Rivaroxaban.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Left atrial appendage occlusion</intervention_name>
    <description>Interventional left atrial appendage occlusion with the Amulet or Watchman device</description>
    <arm_group_label>LAAO group</arm_group_label>
    <other_name>Left atrial appendage closure</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NOAC</intervention_name>
    <description>Medical treatment arm. Patients will be treated with one of the available NOAC drugs; Apixaban, Dabigatran, Edoxaban or Rivaroxaban. The specific drug and dose is at the discretion of the treating physician.</description>
    <arm_group_label>NOAC group</arm_group_label>
    <other_name>Edoxaban</other_name>
    <other_name>Apixaban</other_name>
    <other_name>Rivaroxaban</other_name>
    <other_name>Dabigatran</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years

          -  documented non-valvular atrial fibrillation (paroxysmal, persistent or permanent)

          -  Eligible for long-term Novel Oral Anticoagulation (NOAC) therapy

          -  Ischemic stroke within the recent 6 months verified by neuroimaging, or

          -  Transient ischemic attack within 6 months with proven cerebral ischemia based on
             cerebral magnetic resonance imaging (MRI)

        Exclusion Criteria:

          -  Modified rankin scale &gt; 3 at time of enrollment

          -  Glomerular filtration rate (GFR) below 15 ml/min/1.73 m2

          -  Contraindication towards long-term aspirin therapy

          -  Planned combined cardiovascular interventional procedures at the time of enrollment

          -  Terminal illness or cancer with life expectancy less than 2 years.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kasper Korsholm, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Aarhus University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jens Erik Nielsen-Kudsk, MD DMSc Prof</last_name>
    <role>Study Chair</role>
    <affiliation>Aarhus University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dorte Damgaard, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Aarhus University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Søren Paaske Johnsen, MD PhD Prof</last_name>
    <role>Study Chair</role>
    <affiliation>Aalborg University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kasper Korsholm, MD</last_name>
    <phone>004578452254</phone>
    <email>kasperkorsholm@clin.au.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <state>Central Denmark Region</state>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kasper Korsholm, MD</last_name>
      <phone>004578452254</phone>
      <email>kasperkorsholm@clin.au.dk</email>
    </contact>
    <contact_backup>
      <last_name>Jens Erik Nielsen-Kudsk, MD DMSc Prof</last_name>
      <phone>0078452024</phone>
      <email>jensnils@rm.dk</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <state>Region Of Southern Denmark</state>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jacob Pontoppidan, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aalborg University Hospital</name>
      <address>
        <city>Aalborg</city>
        <state>The North Denmark Region</state>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Boris Modrau, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Helsinki University Central Hospital</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Juha Sinisalo, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Turku University Hospital</name>
      <address>
        <city>Turku</city>
        <zip>20521</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Juha Lund, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Haukeland University Hospital</name>
      <address>
        <city>Bergen</city>
        <zip>5021</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erik JS Packer, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital</name>
      <address>
        <city>Göteborg</city>
        <zip>41345</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jacob Odenstedt, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nikola Drca, MD, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Norway</country>
    <country>Sweden</country>
  </location_countries>
  <reference>
    <citation>Zoni-Berisso M, Lercari F, Carazza T, Domenicucci S. Epidemiology of atrial fibrillation: European perspective. Clin Epidemiol. 2014 Jun 16;6:213-20. doi: 10.2147/CLEP.S47385. eCollection 2014. Review.</citation>
    <PMID>24966695</PMID>
  </reference>
  <reference>
    <citation>Marini C, De Santis F, Sacco S, Russo T, Olivieri L, Totaro R, Carolei A. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke. 2005 Jun;36(6):1115-9. Epub 2005 May 5.</citation>
    <PMID>15879330</PMID>
  </reference>
  <reference>
    <citation>Blackshear JL, Odell JA. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann Thorac Surg. 1996 Feb;61(2):755-9. Review.</citation>
    <PMID>8572814</PMID>
  </reference>
  <reference>
    <citation>Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van Putte B, Vardas P; ESC Scientific Document Group. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016 Oct 7;37(38):2893-2962. doi: 10.1093/eurheartj/ehw210. Epub 2016 Aug 27.</citation>
    <PMID>27567408</PMID>
  </reference>
  <reference>
    <citation>Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009 Sep 17;361(12):1139-51. doi: 10.1056/NEJMoa0905561. Epub 2009 Aug 30. Erratum in: N Engl J Med. 2010 Nov 4;363(19):1877.</citation>
    <PMID>19717844</PMID>
  </reference>
  <reference>
    <citation>Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011 Sep 15;365(11):981-92. doi: 10.1056/NEJMoa1107039. Epub 2011 Aug 27.</citation>
    <PMID>21870978</PMID>
  </reference>
  <reference>
    <citation>Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Špinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013 Nov 28;369(22):2093-104. doi: 10.1056/NEJMoa1310907. Epub 2013 Nov 19.</citation>
    <PMID>24251359</PMID>
  </reference>
  <reference>
    <citation>Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011 Sep 8;365(10):883-91. doi: 10.1056/NEJMoa1009638. Epub 2011 Aug 10.</citation>
    <PMID>21830957</PMID>
  </reference>
  <reference>
    <citation>Diener HC, Connolly SJ, Ezekowitz MD, Wallentin L, Reilly PA, Yang S, Xavier D, Di Pasquale G, Yusuf S; RE-LY study group. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol. 2010 Dec;9(12):1157-1163. doi: 10.1016/S1474-4422(10)70274-X. Epub 2010 Nov 6. Erratum in: Lancet Neurol. 2011 Jan;10(1):27.</citation>
    <PMID>21059484</PMID>
  </reference>
  <reference>
    <citation>Hankey GJ, Patel MR, Stevens SR, Becker RC, Breithardt G, Carolei A, Diener HC, Donnan GA, Halperin JL, Mahaffey KW, Mas JL, Massaro A, Norrving B, Nessel CC, Paolini JF, Roine RO, Singer DE, Wong L, Califf RM, Fox KA, Hacke W; ROCKET AF Steering Committee Investigators. Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol. 2012 Apr;11(4):315-22. doi: 10.1016/S1474-4422(12)70042-X. Epub 2012 Mar 7.</citation>
    <PMID>22402056</PMID>
  </reference>
  <reference>
    <citation>Easton JD, Lopes RD, Bahit MC, Wojdyla DM, Granger CB, Wallentin L, Alings M, Goto S, Lewis BS, Rosenqvist M, Hanna M, Mohan P, Alexander JH, Diener HC; ARISTOTLE Committees and Investigators. Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial. Lancet Neurol. 2012 Jun;11(6):503-11. doi: 10.1016/S1474-4422(12)70092-3. Epub 2012 May 8. Erratum in: Lancet Neurol. 2012 Dec;11(12):1021.</citation>
    <PMID>22572202</PMID>
  </reference>
  <reference>
    <citation>Rost NS, Giugliano RP, Ruff CT, Murphy SA, Crompton AE, Norden AD, Silverman S, Singhal AB, Nicolau JC, SomaRaju B, Mercuri MF, Antman EM, Braunwald E; ENGAGE AF-TIMI 48 Investigators. Outcomes With Edoxaban Versus Warfarin in Patients With Previous Cerebrovascular Events: Findings From ENGAGE AF-TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48). Stroke. 2016 Aug;47(8):2075-82. doi: 10.1161/STROKEAHA.116.013540. Epub 2016 Jul 7.</citation>
    <PMID>27387994</PMID>
  </reference>
  <reference>
    <citation>Gadsbøll K, Staerk L, Fosbøl EL, Sindet-Pedersen C, Gundlund A, Lip GYH, Gislason GH, Olesen JB. Increased use of oral anticoagulants in patients with atrial fibrillation: temporal trends from 2005 to 2015 in Denmark. Eur Heart J. 2017 Mar 21;38(12):899-906. doi: 10.1093/eurheartj/ehw658.</citation>
    <PMID>28110293</PMID>
  </reference>
  <reference>
    <citation>Hellfritzsch M, Husted SE, Grove EL, Rasmussen L, Poulsen BK, Johnsen SP, Hallas J, Pottegård A. Treatment Changes among Users of Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation. Basic Clin Pharmacol Toxicol. 2017 Feb;120(2):187-194. doi: 10.1111/bcpt.12664. Epub 2016 Oct 28.</citation>
    <PMID>27580086</PMID>
  </reference>
  <reference>
    <citation>Reddy VY, Sievert H, Halperin J, Doshi SK, Buchbinder M, Neuzil P, Huber K, Whisenant B, Kar S, Swarup V, Gordon N, Holmes D; PROTECT AF Steering Committee and Investigators. Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial. JAMA. 2014 Nov 19;312(19):1988-98. doi: 10.1001/jama.2014.15192. Erratum in: JAMA. 2015 Mar 10;313(10):1061.</citation>
    <PMID>25399274</PMID>
  </reference>
  <reference>
    <citation>Holmes DR Jr, Kar S, Price MJ, Whisenant B, Sievert H, Doshi SK, Huber K, Reddy VY. Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J Am Coll Cardiol. 2014 Jul 8;64(1):1-12. doi: 10.1016/j.jacc.2014.04.029. Erratum in: J Am Coll Cardiol. 2014 Sep 16;64(11):1186.</citation>
    <PMID>24998121</PMID>
  </reference>
  <reference>
    <citation>Reddy VY, Doshi SK, Kar S, Gibson DN, Price MJ, Huber K, Horton RP, Buchbinder M, Neuzil P, Gordon NT, Holmes DR Jr; PREVAIL and PROTECT AF Investigators. 5-Year Outcomes After Left Atrial Appendage Closure: From the PREVAIL and PROTECT AF Trials. J Am Coll Cardiol. 2017 Dec 19;70(24):2964-2975. doi: 10.1016/j.jacc.2017.10.021. Epub 2017 Nov 4.</citation>
    <PMID>29103847</PMID>
  </reference>
  <reference>
    <citation>Boersma LV, Schmidt B, Betts TR, Sievert H, Tamburino C, Teiger E, Pokushalov E, Kische S, Schmitz T, Stein KM, Bergmann MW; EWOLUTION investigators. Implant success and safety of left atrial appendage closure with the WATCHMAN device: peri-procedural outcomes from the EWOLUTION registry. Eur Heart J. 2016 Aug;37(31):2465-74. doi: 10.1093/eurheartj/ehv730. Epub 2016 Jan 27.</citation>
    <PMID>26822918</PMID>
  </reference>
  <reference>
    <citation>Tzikas A, Shakir S, Gafoor S, Omran H, Berti S, Santoro G, Kefer J, Landmesser U, Nielsen-Kudsk JE, Cruz-Gonzalez I, Sievert H, Tichelbäcker T, Kanagaratnam P, Nietlispach F, Aminian A, Kasch F, Freixa X, Danna P, Rezzaghi M, Vermeersch P, Stock F, Stolcova M, Costa M, Ibrahim R, Schillinger W, Meier B, Park JW. Left atrial appendage occlusion for stroke prevention in atrial fibrillation: multicentre experience with the AMPLATZER Cardiac Plug. EuroIntervention. 2016 Feb;11(10):1170-9. doi: 10.4244/EIJY15M01_06.</citation>
    <PMID>25604089</PMID>
  </reference>
  <reference>
    <citation>Landmesser U, Schmidt B, Nielsen-Kudsk JE, Lam SCC, Park JW, Tarantini G, Cruz-Gonzalez I, Geist V, Della Bella P, Colombo A, Zeus T, Omran H, Piorkowski C, Lund J, Tondo C, Hildick-Smith D. Left atrial appendage occlusion with the AMPLATZER Amulet device: periprocedural and early clinical/echocardiographic data from a global prospective observational study. EuroIntervention. 2017 Sep 20;13(7):867-876. doi: 10.4244/EIJ-D-17-00493.</citation>
    <PMID>28649053</PMID>
  </reference>
  <reference>
    <citation>Sahay S, Nombela-Franco L, Rodes-Cabau J, Jimenez-Quevedo P, Salinas P, Biagioni C, Nuñez-Gil I, Gonzalo N, de Agustín JA, Del Trigo M, Perez de Isla L, Fernández-Ortiz A, Escaned J, Macaya C. Efficacy and safety of left atrial appendage closure versus medical treatment in atrial fibrillation: a network meta-analysis from randomised trials. Heart. 2017 Jan 15;103(2):139-147. doi: 10.1136/heartjnl-2016-309782. Epub 2016 Sep 1.</citation>
    <PMID>27587437</PMID>
  </reference>
  <reference>
    <citation>Tzikas A, Holmes DR Jr, Gafoor S, Ruiz CE, Blomström-Lundqvist C, Diener HC, Cappato R, Kar S, Lee RJ, Byrne RA, Ibrahim R, Lakkireddy D, Soliman OI, Näbauer M, Schneider S, Brachman J, Saver JL, Tiemann K, Sievert H, Camm AJ, Lewalter T. Percutaneous left atrial appendage occlusion: the Munich consensus document on definitions, endpoints and data collection requirements for clinical studies. EuroIntervention. 2016 May 17;12(1):103-11. doi: 10.4244/EIJV12I1A18. Review.</citation>
    <PMID>27173870</PMID>
  </reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>July 6, 2018</study_first_submitted>
  <study_first_submitted_qc>August 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 22, 2018</study_first_posted>
  <last_update_submitted>November 19, 2019</last_update_submitted>
  <last_update_submitted_qc>November 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Left atrial appendage occlusion</keyword>
  <keyword>Novel oral anticoagulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rivaroxaban</mesh_term>
    <mesh_term>Apixaban</mesh_term>
    <mesh_term>Edoxaban</mesh_term>
    <mesh_term>Dabigatran</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

